Onsdag 19 Februari | 03:11:29 Europe / Stockholm

Kalender

Tid*
2025-08-29 07:00 Kvartalsrapport 2025-Q2
2025-05-28 N/A Årsstämma
2025-03-18 21:40 Bokslutskommuniké 2024
2025-01-14 - Split OBSRV 15:1
2025-01-07 - Extra Bolagsstämma 2025
2024-08-26 - Kvartalsrapport 2024-Q2
2024-05-27 - X-dag ordinarie utdelning OBSRV 0.00 NOK
2024-05-24 - Årsstämma
2024-03-13 - Bokslutskommuniké 2023
2023-11-22 - Extra Bolagsstämma 2023
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-30 - X-dag ordinarie utdelning OBSRV 0.00 NOK
2023-05-26 - Årsstämma
2023-02-17 - Bokslutskommuniké 2022
2022-11-03 - 15-10 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning OBSRV 0.00 NOK
2022-06-03 - Årsstämma
2022-03-29 - Bokslutskommuniké 2021
2022-02-04 - Extra Bolagsstämma 2022
2021-11-03 - Kvartalsrapport 2021-Q3
2021-08-20 - Kvartalsrapport 2021-Q2
2021-05-25 - X-dag ordinarie utdelning OBSRV 0.00 NOK
2021-05-21 - Årsstämma
2021-05-12 - Kvartalsrapport 2021-Q1
2021-02-23 - Bokslutskommuniké 2020
2020-11-03 - Kvartalsrapport 2020-Q3
2020-08-18 - Kvartalsrapport 2020-Q2
2020-07-01 - X-dag ordinarie utdelning OBSRV 0.00 NOK
2020-06-30 - Årsstämma
2020-06-16 - Extra Bolagsstämma 2020
2020-05-12 - Kvartalsrapport 2020-Q1
2020-02-25 - Bokslutskommuniké 2019

Beskrivning

LandNorge
ListaOAX Equities
SektorHälsovård
IndustriMedicinteknik
Observe Medical är ett norskt bolag verksamma inom medicinteknik. Bolaget bedriver utveckling av tekniska instrument som används inom intensivvården. Produkterna säljs under olika varumärken och är särskilt specialiserade för urinmätning. Störst verksamhet återfinns inom den nordiska samt europeiska marknaden. Bolaget kom till som en avknoppning från Navamedic och har sitt huvudkontor i Oslo, Norge.
2024-12-17 19:30:38
Oslo, 17 December 2024

Reference is made to the announcement by Observe Medical ASA (the "Company" or
"Observe Medical", OSE ticker "OBSVR") on 5 December 2024 regarding the final
results of the subsequent offering in the Company and the waiver of the
condition for completion of the share capital increase of NOK 10,630,629.88,
through the issuance of 40,887,038 new shares to Navamedic ASA, at a
subscription price of 0.40 per share, in connection with the conversion by
Navamedic ASA of a loan amount of NOK 16,354,815.20 under a loan from Navamedic
ASA to the Company (the "Loan Conversion").

The Loan Conversion has today been completed through the registration of the
share capital increase pertaining to the Loan Conversion with the Norwegian
Register of Business Enterprises (Nw. Foretaksregisteret). The Company's
registered share capital is NOK 75,107,805.50 divided into 288,876,175 shares,
each with a nominal value of NOK 0.26.

The new shares will be issued in the Norwegian Central Securities Depository (ES
-OSL) on the listed ISIN NO 0010865009 and are expected to be delivered to
Navamedic ASA's ES-OSL account later today on 17 December 2024.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Jørgen Mann, CEO Observe Medical

Mobile: +45 408 67 558

E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical

Mobile: +47 958 12 765

E-mail: johan.fagerli@observemedical.com

About Observe Medical:

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialisation of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.